Pulmonx (NASDAQ:LUNG) Announces Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Pulmonx (NASDAQ:LUNG) issued its quarterly earnings data on Wednesday. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12, Zacks reports. The firm had revenue of $23.77 million during the quarter, compared to analysts’ expectations of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. Pulmonx updated its FY 2025 guidance to EPS.

Pulmonx Trading Up 32.2 %

Shares of Pulmonx stock opened at $8.78 on Friday. Pulmonx has a 52-week low of $5.46 and a 52-week high of $14.53. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The business’s 50 day simple moving average is $6.48 and its 200 day simple moving average is $6.75.

Analysts Set New Price Targets

LUNG has been the subject of several research analyst reports. Wells Fargo & Company lowered their price objective on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Stifel Nicolaus lowered their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Finally, Citigroup reaffirmed a “neutral” rating and set a $7.50 price target (down previously from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pulmonx presently has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Insider Transactions at Pulmonx

In related news, General Counsel David Aaron Lehman sold 5,497 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $6.19, for a total value of $34,026.43. Following the completion of the transaction, the general counsel now owns 197,851 shares of the company’s stock, valued at approximately $1,224,697.69. This trade represents a 2.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Geoffrey Beran Rose sold 4,376 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.18, for a total transaction of $27,043.68. Following the sale, the insider now directly owns 291,057 shares in the company, valued at $1,798,732.26. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,199 shares of company stock valued at $76,259 in the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.